Literature DB >> 32282933

Dermatological adverse events associated with use of oral mechanistic target of rapamycin inhibitors in a cohort of individuals with tuberous sclerosis complex.

D J Pithadia1,2, A M Treichel1,2, A M Jones2, P Julien-Williams2, T Machado2, J Moss2, T N Darling1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32282933      PMCID： PMC8325983          DOI： 10.1111/bjd.19124

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   11.113


× No keyword cloud information.
  8 in total

1.  mTOR signaling promotes stem cell activation via counterbalancing BMP-mediated suppression during hair regeneration.

Authors:  Zhili Deng; Xiaohua Lei; Xudong Zhang; Huishan Zhang; Shuang Liu; Qi Chen; Huimin Hu; Xinyue Wang; Lina Ning; Yujing Cao; Tongbiao Zhao; Jiaxi Zhou; Ting Chen; Enkui Duan
Journal:  J Mol Cell Biol       Date:  2015-01-20       Impact factor: 6.216

Review 2.  Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer.

Authors:  Mark S Chambers; Hope S Rugo; Jennifer K Litton; Timothy F Meiller
Journal:  J Am Dent Assoc       Date:  2018-02-10       Impact factor: 3.634

3.  Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects.

Authors:  Emmanuel Mahé; Emmanuel Morelon; Sophie Lechaton; Jean-Christophe Drappier; Yves de Prost; Henri Kreis; Christine Bodemer
Journal:  J Am Acad Dermatol       Date:  2006-07       Impact factor: 11.527

Review 4.  Acneiform Rash Induced by EGFR Inhibitors: Review of the Literature and New Insights.

Authors:  Gabriella Fabbrocini; Luigia Panariello; Gemma Caro; Sara Cacciapuoti
Journal:  Skin Appendage Disord       Date:  2015-02-13

Review 5.  Mammalian target of rapamycin inhibitor-associated stomatitis.

Authors:  Christine B Boers-Doets; Judith E Raber-Durlacher; Nathaniel S Treister; Joel B Epstein; Anniek B P Arends; Diede R Wiersma; Rajesh V Lalla; Richard M Logan; Nielka P van Erp; Hans Gelderblom
Journal:  Future Oncol       Date:  2013-12       Impact factor: 3.404

Review 6.  mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex.

Authors:  David Neal Franz; Darcy Andrew Krueger
Journal:  Am J Med Genet C Semin Med Genet       Date:  2018-10-11       Impact factor: 3.908

7.  Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: A case report and literature review.

Authors:  Hua Zheng; Hongmei Zhang; Tongmei Zhang; Qunhui Wang; Fanbin Hu; Baolan Li
Journal:  Exp Ther Med       Date:  2016-06-16       Impact factor: 2.447

8.  Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study.

Authors:  John J Bissler; J Chris Kingswood; Elzbieta Radzikowska; Bernard A Zonnenberg; Elena Belousova; Michael D Frost; Matthias Sauter; Susanne Brakemeier; Petrus J de Vries; Noah Berkowitz; Maurizio Voi; Severine Peyrard; Klemens Budde
Journal:  PLoS One       Date:  2017-08-09       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.